|Chemical and physical data|
|Molar mass||423.600 g·mol−1|
|3D model (JSmol)|
JWH-373 ([5-(2-butylphenyl)-1-pentylpyrrol-3-yl]-naphthalen-1-ylmethanone) is a synthetic cannabinoid from the naphthoylpyrrole family which acts as an agonist of the CB1 (Ki = 60 ± 3nM) and CB2 (Ki = 69 ± 2nM) receptors, with a slight selectivity for the former. JWH-373 was first synthesized in 2006 by John W. Huffman and colleagues to examine the nature of ligand binding to the CB1 receptor.
In the United States JWH-373 is not federally scheduled, although some states have passed legislation banning the sale, possession, and manufacture of JWH-373.
In Canada, JWH-373 and other naphthoylpyrrole-based cannabinoids are Schedule II controlled substances under the Controlled Drugs and Substances Act.
In the United Kingdom, JWH-373 and other naphthoylpyrrole-based cannabinoids are considered Class B drugs under the Misuse of Drugs Act 1971.